Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until June, 2020.

  1. SBIR PHASE I, TOPIC 239 HIGH-THROUGHPUT SELECTION OF APTAMERS AGAINST CANCER BIOM

    SBC: Accacia International LLC            Topic: N/A

    N/A

    SBIR Phase I 2007 Department of Health and Human Services
  2. T7 RNA polymerase engineering and RNA amplification

    SBC: Accacia International LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Expanding use of microarray systems for global gene expression profiling is leading biological research, providing diagnostic and prognostic value to physicians and facilitating target discovery during drug and vaccine development. There is strong interest in extending this microarray capability to more RNA-limited material to the point that a single cell can b ...

    STTR Phase II 2007 Department of Health and Human Services
  3. Development of a Lightweight, Durable, Adjustable Composite Backrest

    SBC: ACCESSIBLE DESIGNS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): We have designed a prototype lightweight, sturdy, user adjustable ergonomically designed backrest support for ultralight weight wheelchairs that will provide necessary postural support and provide a variety of positions to ease dressing, propulsion, and seated comfort. The backrest will improve user comfort, function, and posture during multiple activities of ...

    SBIR Phase I 2007 Department of Health and Human Services
  4. Multiplex Lyme Disease Diagnostic

    SBC: AGAVE BIOSYSTEMS INC.            Topic: N/A

    DESCRIPTION (provided by investigator): Lyme disease, caused by the gram-negative spirochete Borrelia burgdorferi and transmitted by Ixodid tick species, is the leading vector-borne infectious disease in the United States, with a steady rise in the number of cases reported each year. The most common Lyme disease symptom, the classic bull's-eye rash (erythema migrans or EM rash) in endemic areas, ...

    SBIR Phase I 2008 Department of Health and Human Services
  5. Treatment of Sepsis with Talactoferrin

    SBC: AGENNIX, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Severe sepsis is a major cause of morbidity and mortality throughout the world. It is the leading cause of death in non-coronary intensive care units (ICUs) in the United States, with more than 750,000 cases occurring e very year. This means that in the United States, more than 500 patients die from severe sepsis every day, with 28% to 50% of the patients succu ...

    SBIR Phase I 2007 Department of Health and Human Services
  6. Lactoferrin Enhances Growth and Reduces Nosocomial Infection in Preterm Infants

    SBC: AGENNIX, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): This project aims to develop talactoferrin (TLF, recombinant human lactoferrin) as a therapeutic agent to treat prematurely born neonates. The treatment will be given orally shortly after birth to prevent nosocomial inf ections (NIs) due to abnormal bacterial invasion of neonatal intestinal epithelia and consequently to limit systemic bacteremia and necrotizing ...

    SBIR Phase I 2008 Department of Health and Human Services
  7. Treatment of Sepsis with Talactoferrin

    SBC: AGENNIX, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Severe sepsis is a major cause of morbidity and mortality throughout the world. It is the leading cause of death in non-coronary intensive care units (ICUs) in the United States, with more than 750,000 cases occurring every year. This means that in the United States, more than 500 patients die from severe sepsis every day, with 28% to 50% of the patients succum ...

    SBIR Phase II 2008 Department of Health and Human Services
  8. Molecular Heparan Sulfate Delivery in Guided Tissue Regeneration

    SBC: International Medicine and Biomedical Research            Topic: N/A

    DESCRIPTION (provided by applicant): The role of proteoglycans and carbohydrate polymers such as heparan sulfate in biological processes are becoming better understood, but this new frontier has only begun to be explored. Tissue regeneration is also an emerging frontier. This proposed research, when completed, will make an important contribution to both the proteoglycan and tissue regenerative fie ...

    SBIR Phase I 2007 Department of Health and Human Services
  9. Molecular Delivery of Heparan Sulfate in Wound Regeneration

    SBC: International Medicine and Biomedical Research            Topic: N/A

    DESCRIPTION (provided by applicant): The role of proteoglycans and carbohydrate polymers such as heparan sulfate in biological processes are becoming better understood, but this new frontier has only begun to be explored. Tissue regeneration is also an emerging frontier. This proposed research, when completed, will make an important contribution to both the proteoglycan and tissue regenerative fie ...

    SBIR Phase II 2007 Department of Health and Human Services
  10. SUBCUTANEOUS MONITOR/ALARM FOR CARDIAC ARREST

    SBC: AJ MEDICAL DEVICES, INC.            Topic: N/A

    It is estimated that 220,000 people suffer cardiac arrest each year in the US, of whom only 10,000 survive to hospital discharge. The number of survivors could increase 10-fold if paramedical attention and/or defibrillation were available within a few min

    SBIR Phase II 2008 Department of Health and Human Services
US Flag An Official Website of the United States Government